指南与共识消化系统肿瘤

转移性胰腺癌:ASCO指南更新

Metastatic Pancreatic Cancer: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2020-08-05

本更新针对转移性胰腺癌一线治疗后的治疗选择,ASCO召集专家组进行系统综述,纳入奥拉帕利对比安慰剂的随机对照试验及拉罗替尼、恩曲替尼的I/II期研究,新增或更新了微卫星不稳定高/错配修复缺陷、BRCA突变和TRK融合的检测推荐,并继续支持2018版其余推荐。

要点

  • 所有适合治疗的患者应检测MSI-H/dMMR、BRCA突变和TRK融合以指导治疗选择。
  • 根据检测结果可选用帕博利珠单抗、奥拉帕利、拉罗替尼或恩曲替尼,或参加临床试验。
  • 继续支持2018版指南中关于二线化疗、随访和支持治疗的其余推荐。

核心结论

  • 新增或更新了针对MSI-H/dMMR、BRCA突变和TRK融合的检测推荐,用于筛选适合靶向或免疫治疗的患者。

研究设计与样本

  • ASCO召集专家组进行系统综述,以更新转移性胰腺癌二线治疗推荐。

主要发现

  • 一项奥拉帕利对比安慰剂的随机对照试验、一份拉罗替尼I/II期研究摘要和一份恩曲替尼I/II期研究摘要符合纳入标准并用于更新指南。

关键数值与推荐

  • 所有适合治疗的患者应进行胚系和体细胞MSI-H/dMMR、BRCA突变和TRK融合检测。

临床怎么用

  • 根据检测结果选择帕博利珠单抗、奥拉帕利、拉罗替尼或恩曲替尼,或考虑临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS: ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS: One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS: New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatment-eligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020. PMID: 32755482. doi:10.1200/JCO.20.01364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。